Profound Suppression of Plasma Estrogens by Megestrol Acetate in Postmenopausal Breast Cancer Patients

Clinical Cancer Research

Volumn 2, Issue 9, 1996, Pages 1515-1521

  Lundgren, Steinar ^a   Helle, Svein I ^b   Lønning, Per E ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; APPETITE STIMULANT; DRUG DERIVATIVE; ESTROGEN; ESTRONE; ESTRONE SULFATE; FOLLITROPIN; HYDROCORTISONE; LUTEINIZING HORMONE; MEGESTROL ACETATE; PRASTERONE SULFATE; TESTOSTERONE;

AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; BREAST TUMOR; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE;

ADMINISTRATION, ORAL; AGED; ANDROSTENEDIONE; APPETITE STIMULANTS; AREA UNDER CURVE; BREAST NEOPLASMS; DEHYDROEPIANDROSTERONE SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; ESTRONE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYDROCORTISONE; LUTEINIZING HORMONE; MEGESTROL ACETATE; MIDDLE AGED; POSTMENOPAUSE; TESTOSTERONE;

EID: 0030223027     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Sedlacek, S. M., and Horwitz, K B. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids, 44: 467-484, 1984.
2. Ingle, J. N., Ahmann, D. L., Green, S. J., Edmonson, J H., Creagan, E. T., Hahn, R. G., and Rubin, J. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am. J. Clin. Oncol., 5: 155-160, 1982.
3. Muss, H. B., Wells, H. B., Paschold, E. H., Black. W R., Cooper, M. R., Capizzi, R. L., Christian, R., Cruz, J. M., Jackson, D. V , Powell, B L., Richards, F. I., White, D. R., Zekan, P. J., Spurr, C. L., Pope, E., Case, D., and Morgan, T M. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis-a Phase III trial of the Piedmont Oncology Association. J. Clin. Oncol., 6: 1098-1106, 1988.
4. Lundgren, S., Gundersen, S., Klepp, R., Lønning, P. E., Lund, E., and Kvinnsland, S. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res. Treat., 14: 201-206, 1989.
5. Tseng, L., and Gurpide, E. Effect of progestins on estradiol receptor levels in human endometrium. J. Clin. Endocrinol & Metab., 41: 402-404, 1975.
6. Tseng, L., and Gurpide, E. Induction of human endometrial estradiol dehydrogenase by progestins Endocrinology, 97: 825-833, 1975.
7. Veelen, H. v., Willemse, P. H. B , Sleeker, D. T., Ploeg, E. v. d., Sluiter, W. J., and Doorenbos, H. Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients. Cancer Chemother. Pharmacol., 15: 167-170, 1985.
8. Ewing, T. M., Murphy, L. J , Ng. M-L., Pang, G. Y. N., Lee, C S. L., Watts, C. K. W., and Sutherland, R. L. Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int. J. Cancer, 44: 744-752, 1989.
9. Allegra, J. C., and Kiefer, S M. Mechanism of action of progestational agents. Semin. Oncol., 12: 3-5, 1985
10. Lundgren, S., Lønning, P. E., Utaaker, E., Aakvaag, A , and Kvinnsland, S. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer. I. General findings. J. Steroid Biochem., 30: 99-104, 1990.
11. Lønning, P. E., Dowsett, M., and Powles, T. J. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J. Steroid Biochem. 35: 355-366, 1990.
12. Alexieva-Figusch, J., Blankenstein, M. A., Hop, W C. J., Klijn, J. G. M., Lamberts, S. W. J., Jong, F. H. d., Docter, R., Adlercreutz, H., and Gilse, H. A. v. Treatment of metastatic breast cancer patients with different dosages of megestrol acetate: dose relations, metabolic and endocrine effects. Eur. J. Cancer & Clin. Oncol., 20: 33-40, 1984.
13. Lundgren, S., and Lønning, P. E. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer II: a differential effect of megestrol acetate on serum estrone sulfate and sex hormone binding globulin. J. Steroid Biochem., 36: 105-109, 1990.
14. Ruder, H. J., Loriaux, L., and Lipsett, M. B. Estrone-sulfate: production rate and metabolism in man J. Clin. Invest., 51: 1020-1033, 1972.
15. Lønning, P. E., Johannessen, D. C., and Thorsen, T. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Br. J. Cancer, 60: 107-111, 1989.
16. Lønning, P. E., Helle, S. I., Johannessen, D. C., Adlercreutz, H., Lien, E. A., Tally, M., Ekse, D., Fotsis, T., Anker, G. B., and Hall, K. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I, and insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clin. Endocrinol., 42: 23-30, 1995.
17. Roberts, K. D., Rochefort, J. G., Bleau, G., and Chapdelaine, A. Plasma estrone sulfate levels in postmenopausal women. Steroids, 35: 179-187, 1980.
18. Santner, S. J., Leszcynski, D., Wright, C., Manni, A., Feil, P. D., and Santen, R. J. Estrone sulfate: a potential source of estradiol in human breast cancer tissue. Breast Cancer Res. Treat., 7: 35-44, 1986.
19. Beranek, P. A., Folkerd, E. J., Ghilchik, M. W., and James, V. H. T. 17-β hydroxysteroid dehydrogenase and aromatase activity in breast fat from women with benign and malignant breast tumours. Clin. Endocrinol., 20: 205-212, 1984.
20. Lønning, P. E., and Ekse, D. A sensitive assay for measurement of plasma oestrone sulphate in patients on treatment with aromatase inhibitors. J. Steroid Biochem. Mol. Biol., 55: 409-412, 1995.
21. Lønning, P. E., Kvinnsland, S., Thorsen, T , and Ueland, P. M. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients: preliminary findings. Clin. Pharmacokinet., 13: 393-406, 1987.
22. Longcope, C., Gorbach, S., Goldin, B., Woods, M., Dwyer, J , and Warram, J. The metabolism of estradiol; oral compared to intravenous administration. J. Steroid Biochem., 23: 1065-1070, 1985.
23. Longcope, C., Yesair, D. W., Williams, K. I. H., Callahan, M. M , Bourget, C., Brown, S. K., Carraher, M. S., Flood, C., and Rachwall, P. C. Comparison of the metabolism in dogs of estradiol- 17β following its intravenous and oral administration. J. Steroid Biochem., 13: 1047-1055, 1980.
24. Rowland, M., and Tozer, T. N. Clinical Pharmacokinetics' Concepts and Applications. Philadelphia: Lea & Febiger, 1980.
25. Dowsett, M., Stein, R. C., Mehta, A., and Coombes, R. C. Potency and selectivity of the nonsteroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin. Endocrinol., 32: 623-634, 1990.
26. Demers, L. M. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res. Treat., 50: 95-102, 1994.
27. Lundgren, S. Progestins in breast cancer treatment. Acta Oncol., 31: 709-722, 1992.
28. Vermeulen, A. The hormonal activity of the postmenopausal ovary. J. Clin. Endocrinol. & Metab., 42: 247-253, 1976.
29. Sluijmer, A. V., Heineman, M. A., Jong, F. H. d., and Evers, J. L. H. Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. J. Clin. Endocrinol. & Metab., 80: 2163-2167, 1995.
30. Lønning, P. E., and Lien, E. Mechanisms of action of endocrine treatment in breast cancer. Crit. Rev. Oncol. Hematol., 21: 158-193, 1995.
31. Pommier, R. F , Woltering, E. A., and Fletcher, W. S. Changes in serum sex steroid levels during megestrol acetate therapy. Surg. Oncol., 3: 351-359, 1994.
32. Veelen, H. v., Willemse, P. H. B., Sleijfei, D. T., Sluiter, W. J., and Doorenbos, H. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer. Cancer Treat. Rep., 69: 977-983, 1985.
33. Dowsett, M , Lal, A., Smith, I. E., and Jeffcoate, S. L. The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients. Br. J. Cancer. 55: 311-313, 1987.
34. Briggs, N. H., and Briggs, M. Glucocorticoid properties of progestogens. Steroids, 22: 555-559, 1973.
35. Leinung, M C., Liporace, R., and Miller, C. H. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann. Intern. Med., 122: 843-845, 1995.
36. Tseng, L., Mazella, J., and Sun, B. Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen, and RU 486. Endocrinology US: 1312-1318, 1986.
37. Purohit, A., Lai, L. C., Singh, A., Coldham, N. G., Ghilchik, M. W., Reed, M. J., and James, V. H. T. The effect of medroxyprogesterone acetate on aromatase and DNA polymerase a activities in breast tumours. J. Steroid Biochem., 34: 443-446, 1989.
38. Simpson, H R., Ackerman, G. E., Smith, M. E., and Mendelson, C. R. Estrogen formation in stromal cells of adipose tissue in women: induction by glucocortico-steroids. Proc. Natl. Acad. Sci. USA, 78: 5690-5694, 1981.
39. Reed, M. J., Beranek, P. A., Franks, S., and James, V. H. T. The effect of glucocorticoids on the in vivo conversion of androstenedione to oestrone. Horm. Metab. Res., 18: 635-637, 1986.
40. Alberto. P., Mermillod, B., Kaplan, E., Goldhirsch, A., Obrecht, J-P., Jungi, F., Martz, G., Barrelet, L., and Cavalli, F. A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone. Eur. J. Cancer & Clin. Oncol, 21: 423-428, 1985.
41. Nemoto, T., Rosner, D., Patel, J. K., and Dao, T. L. Aminoglutethimide in patients with metastatic breast cancer. Cancer. 63, 1673-1675, 1989.
42. Garcia-Giralt, E., Ayme, Y., Carton, M., Daban, A., Delozier, T., Fargeot, P., Fumoleau, P., Gorins, A., Guerin, D., Guerin, R., Maillart, P., Mauriac, L., May-Levin, F., Metz. R., Namer, M., Olivier, J. P., Pommatau, E., Pouillart, P., Pujade-Lauraine, E., Rouesse. J., Serrou, B., Vitse, M., and Zylberait, D. Second- and third-line hormontherapy in advanced postmenopausal breast cancer: a multicenter randomized trial comparing medrozyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res. Treat., 24: 139-145, 1992.
43. Murray, R., and Pitt, P. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer Breast Cancer Res. Treat., 35: 249-253, 1995.
44. Nagel, G. A , Wander, H-E., and Blossey, H-C. Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. Cancer Res , 42 (Suppl.): 3442s-3444s, 1982.
45. Hardy, J. R., Powles, T. J , Judson, I R., Sinnett, H D., Ashley, S E., Coombes, R C., and Ellin, C. L. Combination of tamoxifen, aminoglutethimide, danazol, and medroxyprogesterone acetate in advanced breast cancer. Eur J. Cancer, 26, 824-827, 1990
46. Deijk, W. A. v., Blijham, G. H., Mellink, W. A. M., and Meulenberg, P M. M. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol. Cancer Treat. Rep., 69: 85, 1988.
47. Lundgren, S., Lønning, P. E., Aakvaag, A , and Kvinnsland, S Influence of aminoglutethimide on the metabolism of medroxyproges-terone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer. Cancer Chemother. Pharmacol., 27: 101-105, 1990.
48. Lien, E. A., Anker, G., Lønning, P. E., Solheim, E , and Ueland, P. M. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res., 50: 5851-5857, 1990.
49. Lønning, P. E., and Kvinnsland, S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs, 35: 685-710, 1988.